Macquarie Group Ceases to Be Substantial Holder in Australian Clinical Labs

Macquarie Group Limited has announced that it is no longer a substantial holder in Australian Clinical Labs Limited, as its voting power has dropped below the substantial holding threshold. This change, formalized in an Australian Corporations Act Form 605, reflects adjustments in Macquarie's investment interests. The exit may impact shareholder dynamics and perceptions of institutional support for Australian Clinical Labs, although transaction details were not disclosed. The latest analyst rating for Macquarie Group stock is a Buy with a price target of A$235.00.